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Abstract 
We propose a Bayesian hierarchical model applicable to the calibration of the linear-quadratic model of radiation 
dose-response.  Experimental data used in model calibration were taken from a clonogenic survival assay conducted 
on human breast cancer cells (MDA-MB-231) across a range of radiation doses (0 Gy to 6 Gy). Employing Markov-
chain Monte Carlo methods, we calibrated the proposed Bayesian hierarchical model, computed posterior 
distributions for the model parameters and survival fraction dose-response probability densities.  Key contributions 
include the proposal of a model that incorporates multiple sources of inter- and intra-experiment variability 
commonly neglected in the standard frequentist approach and its subsequent application to in vitro experimental 
data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
 
The clonogenic survival assay (first described in [1]) has become synonymous with determining cell survival 
response to ionising radiation. The assay measures the replicative differential between control and treated 
populations; based on the principle that a limited proportion of cells retain reproductive integrity and thus form 
viable colonies [2]. The ability of untreated cells to form colonies, referred to as the plating efficiency, is compared 
against treated groups in order to determine the surviving fraction (SF); where control cells are assigned an SF equal 
to one. Although these relatively simple in vitro assays lack the physiological complexity of in vivo tumours, their 
value in guiding clinical practise should not be underestimated. Variability in radiosensitivity is typically described 
by the shape of the radiation survival curve, allowing comparisons of intrinsic radiosensitivity, radiation quality, 
dose rate effects, fractionation protocols and the impact of environmental factors [3, 4, 5]. Importantly, while the 
predicted magnitude of these variables may be over- or underestimated using in vitro assays, important insights with 
translational relevance can be obtained.  
 
For most clinical low linear energy transfer (LET) X-rays, radiation survival curves can be described in a qualitative 
manner as possessing two distinctive features, corresponding to lethal and sub-lethal lesions [6]. On a typical log-
linear plot these components are evidenced by a linear reduction in survival as an exponential function of dose. As 
dose increases, though still within the range of clinically relevant fractions, the shape of the curve changes as the 
response to cell death resulting from the combined effect of the two components become significant (an effect 
proportional to dose squared) [6, 7]. In quantitative studies, this response is typically modelled using the linear-
quadratic (LQ) model. The LQ model represents the most widely adopted model for predictions of radiation dose 
dependent effects. Applied to single fraction cell survival curves, the LQ model is given by  
 
 𝑆 𝐷;𝛼,𝛽 = exp − 𝛼𝐷 + 𝛽𝐷! , (1) 
 
where 𝑆 denotes the fraction of cells surviving at dose 𝐷, 𝛼 and 𝛽 are model parameters [8]. Of clinical relevance is 
the dose where the contribution to cell death is equal between both linear and quadratic components, referred to as 
the 𝛼/𝛽  ratio [8, 9]. In the clinic, this value provides predictive capability for how tissue will respond to 
radiotherapy, helping to categorise both early and late responding tissue. In general, highly proliferative tumours 
have an 𝛼/𝛽  ratio greater than ten, leading to a linear reduction in cell survival at therapeutic doses; whereas a low 𝛼/𝛽  ratio (i.e. less than three) is characteristic of late responding tissue which requires higher dose fractions to 
achieve equivalent cell death [10, 11]. Determining the 𝛼/𝛽  ratio for each tumour type from simple in vitro 
clonogenic assays can, therefore, help identify optimal dose fractionation size in a tumour specific manner. 
However, despite widespread adoption of the LQ-formalism, concern exists relating to the accuracy of the model for 
high-dose hypofractionation protocols such those applied in stereotactic body radiotherapy (SBRT) [12, 13]. Pre-
clinical data indicate that above a certain threshold dose, survival response becomes linear in contrast to the 
continual bending predicted by the LQ-model [14]. In practice the implication for LQ-based treatment plans is an 
underestimation of isoeffective doses for large radiation fractions. This underestimation in conjunction with 
imprecise assumptions of homogeneous radiobiology, variations in tumour density and the impact of the 
microenvironment have necessitated the development of advanced predicative models based on LQ survival curves 
combined with Poisson based tumour control probability models, facilitated in part by functional imaging [15, 16].  
 
We propose a Bayesian hierarchical regression model to estimate the parameters in the LQ model (1) for in vitro 
clonogenic data; a similar Bayesian approach was used for modelling in vitro dose-response data for a 
pharmaceutical agent [17]. It is beyond the scope of the current work to present a full treatment of Bayesian 
methods, and refer to recent tutorial articles [17, 18, 19]. Briefly, Bayesian calibration may be viewed as a means of 
updating subjective beliefs surrounding model parameters based on indirect experimental observations. The 
subjective nature of this approach naturally lends itself to assessing the probability of events in which the concept of 
repeated experiments under controlled conditions is flawed. For instance, assessing an individual patient’s response 
to radiotherapy based on in vitro experiments of ex vivo tumour samples precludes truly identical repeated 
experiments as tumours exhibit significant heterogeneity. Moreover, inter-specimen variability in clonogenic assays 
introduces additional uncertainty in the utilization of these in vitro results to inform clinical decision-making. The 
hierarchical Bayesian approach adopted here may be used to model this variation and incorporate it into the 
predicted dose-response curves. 
 
The focus of this work is to determine probability distributions for the model parameters employing a hierarchical 
Bayesian approach, with the goal of computing the probability density function (pdf) for the survival of cell 
populations under varying doses of irradiation, while comparing our Bayesian approach to the commonly used 
frequentist approach.   
 
2. Materials and Methods 
 
2.1 Experimental Methods 
 
We obtained human breast cancer cells from the American Type Culture Collection (ATCC) and plated a total of 1.4 
x 104 MDA-MB-231 cells in 35mm2 dishes, supplemented with complete culture medium (DMEM+10% FBS) for 
24 h. A schematic diagram showing the structure of the experiment is provided in Figure 1. The cells were irradiated 
at five dose levels, 𝐷!, (l = 5) from 0 Gy to 6 Gy (160 kVp X-rays), trypsinised, counted and re-plated at pre-
determined low seeding densities. At each dose level, we repeated the assay twice, employing different numbers of 
seeded cells. Individual colonies then formed over 11 to 13 days in a humidified incubator at 37°C, in a mixture of 
95% air and 5% CO2 (total colonies formed represented by red and violet dots, Figure 1).  Colonies were fixed and 
stained using 0.4% crystal violet, and counted three times (n = 3) to yield a mean colony count (counted colonies 
represented by violet dots, Figure 1). For the experiment analysed here, the assay was repeated three times (m = 3). 
Raw data (i.e. cell counts) obtained here may be found in [20].  
 
2.2 Frequentist Analysis  
 
We calculate plating efficiency, 𝑃, as the mean colony count divided by the number of seeded cells. We then 
average 𝑃 obtained for each of the two repeat cell numbers to obtain the mean plating efficiency per experiment 𝑗. 
We compute the survival fraction, 𝑆!!, as the mean plating efficiency at a given non-zero dose 𝐷𝑖 (𝑖 ≥ 1) divided by 
mean plating efficiency at no dose (i.e. 𝐷1 = 0Gy). The survival fraction per dose is then computed for each 
experiment. After completion of the above calculation, (1) was fit to the data employing the least squares method 
using the Python module lmfit [21]. In this approach, we consider two conceptual understandings of data collection 
and pooling between the experiments. In the first, we may view each experiment as independent, whereby we obtain 
distinct and independent parameter values 𝛼!, 𝛽! for each experiment j by analysing each experiment separately. In 
the second, we assume that the experiments are totally dependent, with a single set of parameter values 𝛼, 𝛽 across 
all experiments obtained by analysing all data pooled together.  We obtained a measure of goodness-of-fit, e.g., 𝑅!, 
and a confidence interval on the parameters 𝛼, 𝛽. These results are shown in Figure 2.  Note that fitting the LQ 
model to the individual experiments (Fig. 2B), i.e., no pooling, gave spurious estimates for parameters 𝛼!, 𝛽! and 
confidence intervals (not shown), which is not very useful in predicting dose-response behavior. 
 
Inevitably, there is some variation in our measured cell counts, though this is not explicitly propagated through to 
the survival fraction shown in Figure 2, as it is derived employing the mean values only. For example, in the first of 
the three experiments performed here, at 1.5 Gy, we obtain three counts (74, 74 and 89) for 200 initially seeded 
cells, and a further three (132, 110, and 116) for 400 initially seeded cells, yielding mean plating efficiencies of 
0.395 and 0.298, respectively [20]. The average of these two values is then used to compute survival fraction for this 
experiment and dose level; and this technique is subsequently repeated for all other dose levels points and repeated 
experiments. Clearly, there is variation between the six colony counts at the two levels, though this variation is not 
explicitly propagated through to the survival fraction shown in Figure 2 as it is derived employing the mean values 
only.  The Bayesian approach described below allows us to incorporate this uncertainty in our model predictions, 
and it allows for us to consider partial pooling, between the extreme cases described above. 
 
2.3 Bayesian Hierarchical Model 
 
We propose a Bayesian hierarchical model to assess the effect of dose on the proportion of cells surviving 
irradiation. In addition to inter-experiment variability, we consider measurement error between replicates and 
variability in cell survival and in colony formation.  Thus, we may incorporate this intra-experiment variability into 
our model predictions. This is in contrast to the frequentist approach, in which this variability is lost when 
computing the plating efficiency using the mean colony count.  Here, we do not compute P, but instead input 
directly all of the repeated colony counts into our model.  The cell survival and colony formation is modelled by a 
Binomial distribution (i.e. each plated cell survives and forms a colony with a probability dependent on radiation 
dose and plating efficiency). The measurement of the colonies is modelled as a Poisson distribution (i.e. the number 
of times a colony is counted is Poisson distribution with parameter 𝜆). Finally, the weak inter-experiment 
dependence is modelled by considering the hyperparameters in the prior distributions for 𝛼!  and 𝛽!  as drawn from a 
common population distribution.  
 
Given the LQ model (1) and the definition of plating efficiency 𝑃, we model the number of colonies formed 𝐶!!   
(violet and red dots in Figure 1) as binomially distributed, so that  
 
 𝐶!!|𝛼! ,𝛽! ,𝑃! ∼ 𝐵𝑖𝑛 𝑛!! , 𝑆 𝐷!;𝛼! ,𝛽! 𝑃! , (2) 
 
where 1 ≤ 𝑖 ≤ 𝑙  denotes the dose level, 1 ≤ 𝑗 ≤ 𝑚  denotes the experiment number and 𝑛!! is the (known) number of 
plated cells. During the measurement of the colonies the experimentalist may count each colony multiple times, or 
not at all. As such, we consider the total count of cells as the sum of 𝐶!! Poisson distributions with common 
parameter 𝜆. Therefore, we model the number of colonies counted 𝑁!,!!    (violet dots in Figure 1)  as Poisson 
distributed, so that  
 
 𝑁!,!! |𝐶!! , 𝜆 ∼ 𝑃𝑜 𝜆𝐶!! , (3) 
 
where 1 ≤ 𝑘 ≤ 𝑛  denotes the replicant number.  
 
We note that the same experimentalist conducted all counts in this study and, therefore, we naturally employ a 
common 𝜆 (𝜆 = 1)  throughout. However, if we considered data with multiple experimentalists conducting the count 
we may utilise multiple 𝜆 (potentially in a hierarchical manner) to assess the performance in the count.  
 
The final stage in the construction of our model is to specify prior distributions on the model parameters 𝛼 and 𝛽 
and the hyperparameters 𝜎𝛼 and 𝜎𝛽, representing the respective variances of the model parameters.  In contrast to 
the approach described in section 2.2, we incorporate partial pooling between experiments, allowing us to model the 
uncertainty in the regression coefficients of the different experiments, while informing these coefficients based on 
the hyperparameters describing their prior distributions as drawn from a common population distribution. When 
considering the plating efficiency, 𝑃, we discount interdependence between experiments and impose the prior 
distribution 𝑏𝑒𝑡𝑎(1.5, 2), which is informed from prior experience of conducting similar assays for this cell line. 
The biological intuition here is that it is natural to suppose that the posterior distributions for 𝛼 and 𝛽 should be 
identical for a given cell line and experimental setup. However, there are typically a priori unquantified variations 
that occur during the experiment. The population level hyperparameter distributions account for the level of 
similarity imposed between experiments (i.e. should we get a common 𝛼 and 𝛽 across all experiments; is there 
complete independence between each experiment; or, do we expect that the values obtained in each experiment 
should be similar to some extent, though different in each experiment).  
 
Given prior knowledge on the typical dose-response curves for this cell line [22], we chose weakly informative half-
normal prior distributions on the parameters 𝛼! and 𝛽!, so that they are constrained to be positive and large values 
are unlikely:
 
 
 𝛼! ∼ 𝐻𝑁(𝜎!!) 𝛽! ∼ 𝐻𝑁 𝜎!! . 
 
Due to our lack of a priori knowledge on the respective hyper-parameters, 𝜎𝛼 and 𝜎𝛽, we imposed weakly 
informative half-Cauchy prior distributions in line with [23, 24] 
 𝜎! ∼ 𝐻𝐶(𝛾) 𝜎! ∼ 𝐻𝐶 𝛾 , 
 
where 𝛾 reflects the degree of pooling imposed on the values of 𝛼!  and 𝛽!  across the experiments, with 𝛾 → 0 
implying total pooling and 𝛾 → ∞ implying no pooling. These priors were chosen to be weakly informative, but 
constrained so that 𝛼,𝛽,𝜎! ,𝜎! ≥ 0. Further discussion regarding selection of priors for variance parameters in 
hierarchical models can be found in [24]. 
  
To perform the inference for the Bayesian hierarchical model we employ MCMC to generate posterior distributions 
of 𝛼 and 𝛽 in the LQ model, and their associated hyper-parameters (𝜎! and 𝜎!). We refer to [25, 26, 27] and the 
references cited therein for a comprehensive discussion of Markov chains and MCMC. In order to assess whether 
the parameter space has been well-explored by the chain, and that it has converged to the equilibrium distribution we 
calculate the Gelman-Rubin scale reduction factor [28], where a value of less than 1.1 suggests that the chains have 
converged to a stationary distribution. The results of the convergence assessment are contained in Appendix A. The 
code used to run the MCMC scheme for the Bayesian hierarchical model described in this section is available in 
both R and Python, and can be found at [29]. In R we used the package rjags [30], which provides an interface to the 
JAGS MCMC library [31]. In Python, we used the statistical package pymc3 [32].  
 
 
 
3. Results  
 
Figure 2 shows the computed fit and 95% confidence intervals based on calibrating (1) adopting the frequentist 
approach described in Section 2.2. Figure 3 shows the posterior pdfs for the model parameters and associated hyper-
parameters obtained from calibrating (1) using the hierarchical Bayesian approach set out in Section 2.3. Figure 4 
shows the computed posterior median and 95 % credible region for dose-dependent survival. This plot was 
generated by drawing from the posterior distributions of 𝛼 and 𝛽 (i.e. the posterior distributions shown in Figure 3) 
computing survival fractions at a range of dose values based on (1). Figure 5 provides a comparison between 
frequentist and Bayesian approaches. 
4. Discussion 
We propose a Bayesian hierarchical model to estimate the radiation dose response of human breast cancer cells, 
employing experimental clonogenic survival data. The resulting model predictions account for the uncertainty in 
survival fraction for a given dose as a result of inter-experiment variation, common with the frequentist approach 
used in these assays. Additionally, the hierarchical Bayesian model we propose explicitly accounts for uncertainty in 
plating efficiency in an individual experiment and between replicates of cell count (intra-experiment variability). 
This hierarchical model allows us to quantify and utilise this variation in repeated measurements taken from both the 
control and the irradiated cell populations in our model prediction. Instead of confidence intervals, commonly 
reported with frequentist methods, we obtain posterior pdfs for the model parameters 𝛼𝑗 and 𝛽j for each experiment 
as shown in Figure 3. With the hierarchical Bayesian approach, we obtain a model that lies somewhere between the 
two frequentist approaches described in Section 2.2, resulting from the common population distributions employed 
in the selection of the prior distributions on the model parameters, noting we could easily alter the degree of pooling 
by selecting other values of 𝛾. 
  
Variation in dose response is reflected in the thickness of the shaded area in the plot of survival fraction against dose 
shown in Figure 4. Contrasting this against the results obtained from the frequentist approach shown Figure 2, we 
can remark that there is increased information regarding the uncertainty of the model predictions in our Bayesian 
model. In the frequentist approach, we have neglected multiple sources of uncertainty by averaging the repeated 
measurements; by using only the mean survival fraction per dose per experiment, the frequentist method only 
accounts for the inter-experiment variation, while the Bayesian approach accounts for uncertainty in cell counting 
and variations between replicates, in addition to the inter-experiment variation. The Bayesian approach offers a 
further advantage in that we can immediately calculate intervals that contain the parameters within a desired 
probability, instead of the less intuitive concept of confidence intervals typically employed with frequentist methods. 
In particular, it is straightforward to compute clinically relevant quantities of interest such as the probability that the 
survival fraction at a given dose is lower than a specified value (i.e. 𝑝(𝑆 𝐷 < Val)).  
The Bayesian approach used in this paper offers a large degree of flexibility, and although this requires the user to 
make a number of modelling decisions regarding priors and their hyper-parameters, there are well-established 
choices in the literature. An accessible tutorial for fitting Bayesian models, including a discussion of prior 
distributions, to a tumour growth model can be found in [15] and for an in-depth discussion of the choice of variance 
parameters in prior distributions see [19]. The choice of priors and hyper-parameters should be informed as much as 
possible by expert knowledge and no one choice should be considered a panacea. 
 
In Figure 2 and Figure 3 we obtain results consistent with parameter values reported in [22]. The posteriors for 𝜎𝛼 
and 𝜎! shown in Figure 3 reflect the variation in the model parameters across the experiments. The posterior 
distributions for plating efficiency show more colonies formed in experiment 1 than in experiments 2 and 3, which is 
clearly shown by the positions of the pdfs in Figure 3. This inclusion of variations in plating efficiency in the 
computation of the survival fraction versus dose curve Figure 4 represents a key advantage of the Bayesian 
approach. The posterior distributions shown in Figure 3 are all unimodal, with mean values far from the imposed 
through the choice of prior; thus, vindicating our choice of prior. 
 
To illustrate how results from the Bayesian approach may be used to inform clinical dosing levels, we computed the 
probability distribution of the 𝛼/𝛽 ratio utilizing random draws from the posterior distributions on 𝛼 and 𝛽 shown in 
Figure 5B. This distribution is well within the range of 0-3, indicating that a late response of these cells to radiation 
doses, suggesting that higher dose fractions should be used to treat this cell type. The width of this distribution, 
along with width of the survival fraction versus dose curve in Figure 4 could be indicative of the potential 
effectiveness of a treatment regime that was developed by utilizing the approach outlined in this article. Moreover, 
this approach may be applied to developing population-specific treatment strategies. The dose-response of biopsied 
cells taken from a patient population could be tested using the clonogenic survival assay. Our proposed hierarchical 
Bayesian model could then be applied to generate posterior distributions on 𝛼! and 𝛽!, this time per patient. From 
these, both a survival fraction versus dose curve and the distribution of 𝛼/𝛽  for the patient population could be 
generated. If point estimates are required to comply with current clinical practice, for instance in therapy planning, 
one could compute the median or mode for any of the posterior distributions presented above. 
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Figure 1.  Schematic diagram of the experimental structure and illustration of the Bayesian hierarchical 
approach.  Linear-quadratic (LQ) model (1) parameters 𝛼! and 𝛽! are given per experiment 𝑗. Total colonies 
formed, 𝐶!!, modelled by a binomial distribution (2), are depicted as red and violet dots, with the latter representing 
colonies counted by the experimenter, 𝑁!,!! , represented by a Poisson distribution (3), noting some colonies may 
not be counted and some may be counted more than once. Repeated counts are made by the experimenter, where 𝑘 ∈ 1,𝑛  denotes replicant number.  Hyperparameters 𝜎! and 𝜎! represent variances in the model parameters.  
For the given data, 𝑙 = 5,𝑚 = 3,𝑛 = 3. 
Figure 2: A) Survival fraction versus radiation dose, showing raw data and fit of (1) to the pooled data, using 
least-squares regression, with shaded area depicting the 95 % confidence interval. 𝑅! = 0.981, and best-fit 
parameter values with 95 % CI are: 𝛼 = 0.0223 ± 0.0458 and 𝛽=0.0422 ± 0.0118. B) Survival fraction versus 
radiation dose obtained by fitting the data obtained in each experiment separately, i.e. employing un-pooled data.  
Figure 3: Posterior distributions of the parameters and hyperparameters; 𝛼!, 𝛽!, 𝜎!, 𝜎! and 𝑃!. 
Figure 4: Posterior median of the survival curve obtained employing the Bayesian approach with shaded area 
depicting a 95 % credible region. 
Figure 5: A) Comparison of survival curves obtained using the frequentist and Bayesian approach. B) Posterior 
distribution of the 𝛼/𝛽 ratio pooled across the three experiments. This plot shows the Bayesian marginal pointwise 
posterior median survival fraction and its corresponding frequentist MLE together with 95% confidence interval. 	  	  	  	  	  	  	  	  
 
